Rage Biotech, a therapeutics startup tackling persistent inflammatory illness, has raised $29 million in a Sequence A.
The spherical was led by IP Group Australia and tremendous fund Hostplus, with assist from current traders together with Monash Ventures. The funds will go in the direction of first-in-human scientific trials for Rage’s nasal remedy to deal with inflammatory lung illnesses
The startup’s title is an acronym of Receptor for Superior Glycation Finish-products (RAGE), a receptor concerned in irritation in persistent lung illnesses and different situations.
Rage Bio was based as a spinout between IP Group Australia and Monash, Murdoch and WA universities and the and the Baker and Perron medical analysis institutes, to develop know-how and coverings for inflammatory problems.
Monash College’s College of Medication, Nursing and Well being Sciences, helped develop the corporate’s lead program, RB042, an inhaled remedy for inflammatory lung illnesses.
Newly appointed CEO Dr Siro Perez, who performed an instrumental function in establishing the biotech startup at IP Group, says RB042 has proven promise in pre-clinical exams.
Rage Bio CEO Dr Siro Perez
“I’ve deep conviction within the promise of RB042 to beat persistent illness the place the unmet want is immense and present therapies are restricted to symptom administration,” he mentioned.
“RB042 provides the potential for a disease-modifying remedy in COPD [chronic obstructive pulmonary disease], a market with tens of millions of sufferers worldwide and few efficient choices. We’re dedicated to advancing this program and our broader pipeline to ship life-saving impacts for sufferers.”
Dr Perez most not too long ago led the Life Sciences workforce at IP Group Australia, has cofounded a number of biotech startups, additionally labored in VC at Hadean Ventures, and SAC Capital, and took over from founding CEO Dr Chris Wraight, now Rage’s chief scientific officer.
“Launching Rage Bio and advancing our lead program RB042 has been a outstanding journey,” Wraight mentioned.
“Our platform is constructed on deep scientific experience and a dedication to innovation. As we transfer into the clinic, I’m excited to concentrate on our scientific technique and pipeline growth.”
The startup additionally named Dr Edwin Tucker as chief medical and improvement officer.
IP Group Australia MD Dr Mike Molinari has joined the Rage board.
Monash College senior director of latest ventures and investments, Dr Ingmar Wahlqvist, mentioned: “By backing distinctive founders and science with focused funding, we’re constructing ventures that advance drugs and ship tangible influence for sufferers worldwide.”
